Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas
This study has been terminated.
(Modified dose schedule presented no advantage over previously studied schedule)
Information provided by:
First received: August 7, 2009
Last updated: NA
Last verified: August 2009
History: No changes posted
This phase 1 study of quarfloxin (CX-3543) is designed to test the safety, tolerability, and highest safe dose of this drug when administered intravenously weekly for three weeks of a four week cycle in patients with advanced solid tumors.
Advanced Solid Tumors
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Quarfloxin Administered Intravenously Weekly for Three Weeks of a Four Week Cycle in Patients With Advanced Solid Tumors or Lymphomas
Primary Outcome Measures:
- Maximum tolerated dose (MTD) and Dose limiting toxicity (DLT) [ Time Frame: Cycle 1 ] [ Designated as safety issue: Yes ]
- Recommended Phase 2 dose [ Time Frame: Cycle 1 ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Pharmacokinetics (PK) in humans of intravenously administered quarfloxin [ Time Frame: One month ] [ Designated as safety issue: No ]
- Evaluation of antitumor activity of quarfloxin by objective radiologic assessment [ Time Frame: Every 2 months ] [ Designated as safety issue: No ]
- Pharmacodynamic evaluation of antitumor activity [ Time Frame: Monthly ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||April 2008 (Final data collection date for primary outcome measure)
Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
Quarfloxin is a first-in-class small-molecule targeted cancer therapeutic derived from the validated fluoroquinolone class of drugs. Quarfloxin was rationally designed to target a G-quadruplex (QPLX) DNA structure and disrupt protein-DNA interactions essential to cancer cells. The QPLX targeted by quarfloxin forms within ribosomal DNA (rDNA) and the QPLX is bound by the nucleolin protein.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patients with histologically confirmed solid tumors or lymphomas.
- Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy.
- One or more tumors measurable on radiograph or CT scan, or evaluable disease (e.g., malignant ascites).
- Karnofsky performance status of greater than or equal to 70.
- Life expectancy of at least 3 months.
- Age at least 18 years.
- Patients must have central IV access, or agree to the insertion of a central IV line.
- Normal oxygen saturation by pulse oximetry on room air
- A negative pregnancy test (if female).
- Acceptable liver function as evaluated by laboratory results
- Acceptable renal function as evaluated by laboratory results
- Acceptable hematologic status as evaluated by laboratory results
- No clinically significant urinalysis abnormalities
- Acceptable coagulation status as evaluated by laboratory results
- Fertile men and women must use effective contraceptive methods during the study.
- Seizure disorders requiring anticonvulsant therapy.
- Known brain metastases (unless previously treated and well controlled for a period of greater than or equal to 3 months).
- Severe chronic obstructive pulmonary disease with hypoxemia, or an uncorrectable pulmonary compromise.
- Major surgery, other than diagnostic surgery, within 4 weeks prior to the first dose of test drug.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
- Pregnant or nursing women.
- Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within one month prior to study entry (6 weeks for nitrosoureas or Mitomycin C).
- Unwillingness or inability to comply with procedures required in this protocol.
- Known infection with HIV, hepatitis B, or hepatitis C.
- Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis.
- Patients who are currently receiving any other investigational agent.
- Patients who have exhibited allergic reactions to a similar structural compound (e.g., fluoroquinolones, biological agent or formulation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00955292
|Scottsdale, Arizona, United States |
|San Antonio, Texas, United States |
No publications provided
||C. Padgett, Cylene Pharmaceuticals
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 7, 2009
||August 7, 2009
||United States: Food and Drug Administration
Keywords provided by Cylene Pharmaceuticals:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 17, 2014
Neoplasms by Histologic Type
Immune System Diseases